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The incidence and factors associated with inappropriate use of antifungal medications were studied in a Thai tertiary care center. The incidence of inappropriate antifungal use was 74% (in 42 of 57 patients). Isolation of Candida species from urine (P p .004) was a risk factor, whereas receipt of an infectious diseases consultation (P p .004) was protective.
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It is well recognized that inappropriate antifungal use contributes to the global increase in antifungal resistance and may lead to a variety of adverse outcomes, including unnecessary exposure to medications, persistent infections, and increased costs. 1 This issue has been particularly concerning in developing countries, where antifungal management programs rarely exist. Despite these concerns, the data are limited on the incidence and prevalence of inappropriate antifungal use and the risk factors associated with it. We conducted a prospective study from December 1, 2006 , to June 30, 2007 to assess the incidence of and factors associated with inappropriate use of antifungal medications at a hospital in Thailand.
methods
This study was conducted at Thammasart University Hospital, a 500-bed tertiary care university hospital in central Thailand. Routine antifungal susceptibility testing is performed according to Clinical and Laboratory Standards Institute (CLSI) criteria. 2 Both adult and pediatric infectious diseases consultation services are readily available. There were no existing policies for antifungal drug use at our hospital during the study period. All hospitalized inpatients at least 15 years old who were prescribed antifungal therapy were included. Inpatients receiving oral or intravenous antifungal medications were monitored by the study team until discharge. Each patient who received antifungal therapy was visited 3 times: when the patient first had the antifungal administered; when microbiologic laboratory results (ie, culture results) were available (72 hours to 1 week after sampling, depending on fungal pathogen); and at discharge when the final diagnosis was available. Data were collected regarding each patient's demographic characteristics, comorbidities, and Acute Physiology and Chronic Health Evaluation II (APACHE-II) score, and the antifungal agent prescribed, indication for antifungal prescription, request for infectious diseases consultation, appropriateness of antifungal use, and reasons for any inappropriate antifungal use. Through a review of the medical records, antifungal therapy was classified as empirical treatment for a suspected infection, prophylaxis for fungal opportunistic infection, or treatment for a documented fungal infection. All data were collected by one investigator (A.S.) and recorded into a data collection tool. The prescribing physicians were unaware that the study was being performed at the time of medical chart review. The hospital's institutional review board approved the study.
The criteria used to define the appropriateness of antifungal prescription were adopted from the current edition of Principles and Practices of Infectious Diseases. 3 Specific use categories were modeled after those of Kunin et al. 4 and were modified to fit local practices by an expert panel consisting of 2 infectious diseases physicians who were not directly involved in the clinical care of the study patients. Significant candiduria was defined as a Candida concentration of at least 10 5 cfu/mL in a urine sample. Diagnosis of significant candiduria also required evidence of urinary tract pyuria (defined as a white blood cell count of at least 10 cells/mm 3 , or at least 3 white blood cells per high power field of unspun urine), and recovery of identical Candida isolates from multiple urine samples and/or from samples of blood and urine. 5, 6 Measurements were performed by 2 investigators and any discordance in the assessment of appropriateness was mediated by a third infectious diseases specialist.
Categorical variables were compared using the x 2 or Fisher's exact test, as appropriate, and continuous variables were compared using the Mann-Whitney U test. To evaluate the risk factors associated with inappropriate antifungal use, variables that were present for more than 10% of patients and that had a P value of greater than .20 on univariate analysis or that had a priori clinical significance were entered into backward stepwise logistic regression models. Significant variables that were potential covariates were grouped, and only 1 variable from each group was chosen for entry into the model. The final model was chosen on the basis of biological plausibility and by selecting the logistic regression model with the lowest Ϫ2 log likelihood function. All tests were 2-tailed, and P values less than .05 were considered to be statistically significant.
results
During the study period, antifungal medications were prescribed for 57 patients. The most common sites from which fungus was isolated included the urine (22 [39%] of 57) and bloodstream (17 [30%] of 57). Of the 57 patients, 47 (82%) received antifungal medications for documented infections, 
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). Although the association was not sta-P p .004 tistically significant, patients with an APACHE II score greater than 15 were more likely to receive inappropriate antifungal therapy than were patients with a lower score (aOR, 3.6 [95% CI, 0.9-15.6];
). Patients who had urine culture pos-P p .07 itive for Candida species were more likely to have a central venous line or a urinary catheter than were those without such a culture result (OR, 4.5 [95% CI, 1.2-52.4];
), P p .01 and patients who had an APACHE II score of greater than 15 were more likely to develop renal failure during the hospitalization than were those with a lower score (OR, 5.1 [95% CI, 1.05-46.2];
). P p .03 discussion Felix and colleagues 7 first reported an audit of antifungal use in a tertiary care university hospital in the United Kingdom. The incidence of inappropriate use of antifungal medications was 67%. The most common reasons that antifungal use was inappropriate were inappropriate dose and duration (41%) and inappropriate indication (27%). In Thailand, although many studies regarding the incidence and prevalence of and risk factors for inappropriate antibiotic use have been reported, 8 these studies have not examined the appropriateness of antifungal therapy. To our knowledge, we are the first to describe the high incidence of inappropriate antifungal use in Thailand and emphasize the need to have an antifungal management program.
Although the small sample size may limit our capacity to detect other potential risk factors, our data reveal significant associations between inappropriate antifungal use and the isolation of fungus from the urine and a higher APACHE II score. These associations are not surprising, because most patients with candiduria had central line or urine catheters placed, which led to an increase in the rate of colonization and unnecessary treatment. Patients with a higher APACHE-II score had been exposed to antibiotics, which led to an increase in the rate of colonization and also a higher incidence of renal failure requiring renal dose adjustment. Importantly, patients who initially received inappropriate antifungal therapy tended to receive inappropriate antifungal therapy throughout their hospitalization. As has been consistently shown in studies from developed countries, 9, 10 this study also suggests the benefit of an infectious diseases consultation in guiding appropriate antifungal use in developing countries.
Given the findings of our study, attempts to rectify the inappropriate use of antifungal medications should be focused on educational interventions. The interventions should include dose adjustments in patients with renal failure, improvement in appropriate clinical recognition of significant candiduria, and establishment of antifungal management programs that incorporate infectious diseases consultations.
Further studies to evaluate factors associated with the inappropriate use of antifungal medications and interventions to reduce inappropriate antifungal use in developing countries are needed.
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